Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104


Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.

Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.

Clin Cancer Res. 2013 Sep 1;19(17):4717-27. doi: 10.1158/1078-0432.CCR-12-3891. Epub 2013 Jul 15.


Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE 2nd, McLendon RE, Bigner DD.

Nucl Med Biol. 2012 Jan;39(1):23-34. doi: 10.1016/j.nucmedbio.2011.06.005. Epub 2011 Sep 29.


MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Kuan CT, Wakiya K, Herndon JE 2nd, Lipp ES, Pegram CN, Riggins GJ, Rasheed A, Szafranski SE, McLendon RE, Wikstrand CJ, Bigner DD.

BMC Cancer. 2010 Sep 1;10:468. doi: 10.1186/1471-2407-10-468.


Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.

Kuan CT, Wikstrand CJ, McLendon RE, Zalutsky MR, Kumar U, Bigner DD.

Hybridoma (Larchmt). 2009 Dec;28(6):389-403. doi: 10.1089/hyb.2009.0049.


Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors.

Yang W, Barth RF, Wu G, Huo T, Tjarks W, Ciesielski M, Fenstermaker RA, Ross BD, Wikstrand CJ, Riley KJ, Binns PJ.

J Neurooncol. 2009 Dec;95(3):355-365. doi: 10.1007/s11060-009-9945-x. Epub 2009 Jul 9.


Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.

Yang W, Wu G, Barth RF, Swindall MR, Bandyopadhyaya AK, Tjarks W, Tordoff K, Moeschberger M, Sferra TJ, Binns PJ, Riley KJ, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ.

Clin Cancer Res. 2008 Feb 1;14(3):883-91. doi: 10.1158/1078-0432.CCR-07-1968.


Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.


Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.

Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ.

Clin Cancer Res. 2006 Jun 15;12(12):3792-802.


Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.

Kuan CT, Wakiya K, Dowell JM, Herndon JE 2nd, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1970-82.


Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity.

Rizzieri DA, Wadleigh M, Wikstrand CJ, Mann KP, Sen F, Peterson BL, Niedzwiecki D, Proia AD, Bigner DD.

Leuk Lymphoma. 2005 Oct;46(10):1455-62.


Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.

Yang W, Barth RF, Wu G, Ciesielski MJ, Fenstermaker RA, Moffat BA, Ross BD, Wikstrand CJ.

Clin Cancer Res. 2005 Jan 1;11(1):341-50.


Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN.

Mol Cancer Ther. 2005 Jan;4(1):101-12.


Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R).

Purev E, Cai D, Miller E, Swoboda R, Mayer T, Klein-Szanto A, Marincola FM, Mick R, Otvos L, Wunner W, Birebent B, Somasundaram R, Wikstrand CJ, Bigner D, DeMichele A, Acs G, Berlin JA, Herlyn D.

J Immunol. 2004 Nov 15;173(10):6472-80.


Monoclonal antibodies for brain tumour treatment.

Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD.

Expert Opin Biol Ther. 2004 Sep;4(9):1453-71. Review.


Poliovirus receptor CD155-targeted oncolysis of glioma.

Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M.

Neuro Oncol. 2004 Jul;6(3):208-17.


Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH.

Clin Cancer Res. 2004 May 1;10(9):3216-24.


Phase II trial of gefitinib in recurrent glioblastoma.

Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS.

J Clin Oncol. 2004 Jan 1;22(1):133-42. Epub 2003 Nov 24.


Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.

Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH.

Clin Cancer Res. 2003 Sep 15;9(11):4247-54.


Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD.

J Clin Oncol. 2002 Mar 1;20(5):1389-97.


Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.

Wikstrand CJ, Cole VR, Crotty LE, Sampson JH, Bigner DD.

Cancer Immunol Immunother. 2002 Feb;50(12):639-52. Epub 2001 Dec 8.


Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro.

Hedberg KM, Dellheden B, Wikstrand CJ, Fredman P.

Glycoconj J. 2000 Oct;17(10):717-26.


EGF mutant receptor vIII as a molecular target in cancer therapy.

Kuan CT, Wikstrand CJ, Bigner DD.

Endocr Relat Cancer. 2001 Jun;8(2):83-96. Review. No abstract available.


Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study.

Cokgor I, Akabani G, Friedman HS, Friedman AH, Zalutsky MR, Zehngebot LM, Provenzale JM, Guy CD, Wikstrand CJ, Bigner DD.

Cancer. 2001 May 1;91(9):1809-13.


EGFRvIII as a promising target for antibody-based brain tumor therapy.

Kuan CT, Wikstrand CJ, Bigner DD.

Brain Tumor Pathol. 2000;17(2):71-8. Review.


Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.

Kuan CT, Wikstrand CJ, Archer G, Beers R, Pastan I, Zalutsky MR, Bigner DD.

Int J Cancer. 2000 Dec 15;88(6):962-9.


Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD.

J Clin Oncol. 2000 Nov 15;18(22):3862-72.


Identifying potential tumor markers and antigens by database mining and rapid expression screening.

Loging WT, Lal A, Siu IM, Loney TL, Wikstrand CJ, Marra MA, Prange C, Bigner DD, Strausberg RL, Riggins GJ.

Genome Res. 2000 Sep;10(9):1393-402.


Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor.

McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD.

J Histochem Cytochem. 2000 Aug;48(8):1103-10.


Monoclonal antibody therapy of human gliomas: current status and future approaches.

Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD.

Cancer Metastasis Rev. 1999;18(4):451-64. Review.


Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.

Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH, Friedman HS, Bigner DD.

Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7503-8.


Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE 2nd, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR.

J Clin Oncol. 1998 Jun;16(6):2202-12.


Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha.

Wikstrand CJ, Bigner DD.

J Natl Cancer Inst. 1998 Jun 3;90(11):799-801. No abstract available.


The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD.

J Neurovirol. 1998 Apr;4(2):148-58. Review.


Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.

Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD.

Cancer Res. 1997 Sep 15;57(18):4130-40.


Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD.

Biochem J. 1997 Jun 15;324 ( Pt 3):855-61.


Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE 2nd, Vick NA, Paleologos N, Fredericks RK, Schold SC Jr, Bigner DD.

Clin Cancer Res. 1996 Jun;2(6):963-72.


In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line.

Fredman P, Wikstrand CJ, MÃ¥nsson JE, Reifenberger G, Bigner SH, Rasheed A, Svennerholm L, Bigner DD.

Glycoconj J. 1996 Jun;13(3):391-9.


Tumor antigens in astrocytic gliomas.

Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD.

Glia. 1995 Nov;15(3):244-56. Review.


Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.

Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD.

Cell Growth Differ. 1995 Oct;6(10):1251-9.


Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.

Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR.

Cancer Res. 1995 Oct 1;55(19):4375-82.


Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.

Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD, Pastan I.

Clin Cancer Res. 1995 Aug;1(8):859-64.


Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.

Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al.

Cancer Res. 1995 Jul 15;55(14):3140-8.


Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.

Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pegram CN, et al.

J Neurooncol. 1995;24(1):109-22.


Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin.

He X, Archer GE, Wikstrand CJ, Morrison SL, Zalutsky MR, Bigner DD, Batra SK.

J Neuroimmunol. 1994 Jul;52(2):127-37.


Immunobiology of malignant astrocytomas.

Kurpad SN, Wikstrand CJ, Bigner DD.

Semin Oncol. 1994 Apr;21(2):149-61. Review. No abstract available.


Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization.

Batra SK, Niswonger ML, Wikstrand CJ, Pegram CN, Zalutsky MR, Morrison SL, Bigner DD.

Hybridoma. 1994 Apr;13(2):87-97.


Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro.

Wikstrand CJ, Fredman P, McLendon RR, Svennerholm L, Bigner DD.

Mol Chem Neuropathol. 1994 Feb-Apr;21(2-3):129-38.


Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas.

Wikstrand CJ, Stanley SD, Humphrey PA, Pegram CN, Archer GE, Kurpad S, Shibuya M, Bigner DD.

J Neuroimmunol. 1993 Jul;46(1-2):165-73.


Supplemental Content

Loading ...
Support Center